Health · Developing · 2 min read · Published 2 Nov 2026 · · Updated 2 Nov 2026 ·
Generic HIV-Prevention Injection Receives Tentative Approval
Updated · 2 Nov 2026 ·
A further check on 2 November of Gilead’s published voluntary-licence agreement found Trinidad and Tobago listed in Part A of its territory schedule, at entry 108. That establishes inclusion in the published licensing territory, rather than a local launch. Gilead’s current access page separately prioritises registrations in 18 other countries; Trinidad and Tobago is not in that priority group. Local approval, procurement, stock and patient pricing remain unconfirmed.
Sources: Gilead, published voluntary-licence agreement, Appendix 1 ↗
By the Luk It Hyah newsdesk · Sources · Reporting disclaimer
The Short
Partners report tentative FDA approval of generic lenacapavir and initial supplies planned before year-end. Trinidad and Tobago appears in Gilead’s published licensing territory, but local approval, supply and a patient price remain unconfirmed.
The Full Story
The World Health Organization recommended twice-yearly injectable lenacapavir as an additional HIV-prevention option in July 2025. It is pre-exposure prophylaxis, or PrEP: medicine used to reduce the risk of acquiring HIV. WHO also recommends HIV testing when people start or continue long-acting injectable PrEP.
Sources: WHO guidelines, 14 Jul 2025 ↗
A pricing agreement announced in September 2025 supported development of a generic version by Dr. Reddy’s Laboratories. On Monday 2 November 2026, the Clinton Health Access Initiative (CHAI) said the company had secured tentative US Food and Drug Administration approval, with support from Unitaid and Wits RHI. CNC3 carried an Associated Press report of the announcement that afternoon.
Sources: CHAI, 2 Nov 2026 ↗ · Associated Press via CNC3, 2 Nov, 12:45 p.m. Trinidad time ↗
CHAI says the agreed medicine price is US$40 per person per year for the 120 low- and middle-income countries covered by the voluntary licence. It expects initial supplies before the end of 2026 and wider availability in 2027. These are planned supply arrangements, not confirmation that every eligible country has received the drug.
Sources: CHAI, 2 Nov 2026 ↗
The organisation describes tentative approval as the FDA designation used while the originator product remains under patent, enabling US-government procurement. It says national approvals and work to introduce the medicine remain necessary. Luk It Hyah has reviewed the partners’ announcement, rather than the underlying FDA decision letter.
Sources: CHAI, 2 Nov 2026 ↗
PAHO separately announced a regional procurement pathway in September, stressing that introduction depends on national regulation, clinical protocols, trained staff and programme planning. The material reviewed does not establish a Trinidad and Tobago rollout date, local stock or the price a patient would pay.
Sources: PAHO, 15 Sep 2026 ↗
A further check on 2 November of Gilead’s published voluntary-licence agreement found Trinidad and Tobago listed in Part A of its territory schedule, at entry 108. That establishes inclusion in the published licensing territory, rather than a local launch. Gilead’s current access page separately prioritises registrations in 18 other countries; Trinidad and Tobago is not in that priority group. Local approval, procurement, stock and patient pricing remain unconfirmed.
Sources: Gilead, published voluntary-licence agreement, Appendix 1 ↗
Sources
Reader Photos
Share a related photoPhotos are checked before they appear here. The credit name supplied by each contributor is public.
No reader photos have been published for this article yet.